Base de dados : LILACS
Pesquisa : B04.280.650.160.100.149 [Categoria DeCS]
Referências encontradas : 2 [refinar]
Mostrando: 1 .. 2   no formato [Detalhado]

página 1 de 1

  1 / 2 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-657615
Autor: Zanetti, Flavia; Rudak, Liliana; Micucci, Matías; Conte Grand, Daniela; Luque, Andrea; Russo, Susana; Taboga, Oscar; Pérez, Oscar; Calamante, Gabriela.
Título: Obtención y evaluación preliminar de un virus canarypox recombinante como candidato a vacuna antirrábica / Development and preliminary assessment of a recombinant canarypox virus as an antirabic vaccine candidate
Fonte: Rev. argent. microbiol;44(2):75-84, jun. 2012. ilus, graf, tab.
Idioma: es.
Resumo: En la Argentina, la rabia está circunscripta a algunas provincias del norte. La disponibilidad de nuevas vacunas que eliminen la manipulación del virus rábico y que permitan el control de la enfermedad es de importancia estratégica nacional y regional. Las vacunas basadas en poxvirus recombinantes se han utilizado con éxito como vacunas antirrábicas a nivel mundial. SI bien estos sistemas no están disponibles comercialmente, la plataforma de obtención de virus canarypox (CNPV) recombinantes ya ha sido implementada en nuestro laboratorio. El objetivo de este trabajo fue obtener y evaluar un candidato a vacuna antirrábica basado en CNPV recombinantes que expresan la glicoproteína G (RG) del virus rábico (RV). Se construyó un virus recombinante que expresa la secuencia codificante de RG (CNPV-RG). La inoculación de ratones con este virus indujo altos títulos de anticuerpos seroneutralizantes de RV (3,58 y 9,76 Ul/ml después de una o dos inmunizaciones, respectivamente) y protegió al 78 % de los animales desafiados intracerebralmente con RV. Además, se determinó que el CNPV-RG posee una potencia relativa de 3,5 Ul/ml. Los resultados obtenidos constituyen la primera etapa en la evaluación del CNPV-RG como candidato a vacuna antirrábica. Se requerirán nuevos ensayos para confirmar su utilidad en especies de interés veterinario.

In Argentina, rabies is limited to some northern provinces. Availability of new vaccines abolishing the handling of the rabies virus and allowing disease control has regional and national strategic importance. Vaccines based on recombinant poxviruses have been successfully used as antirabic vaccines worldwide. Although these systems are not commercially available, the platform to obtain recombinant canarypox viruses (CNPV) has been previously set up in our laboratory. The aim of this work was the development and evaluation of an antirabic vaccine candidate based on recombinant CNPV expressing the rabies virus (RV) glycoprotein G (RG). A recombinant virus (CNPV-RG) expressing the RG coding sequence was designed. Inoculation of mice with this virus induced high RV seroneutralizing antibodies (3.58 and 9.76 lU/ml after 1 or 2 immunizations, respectively) and protected 78% of intracerebrally RV-challenged animals. In addition, it was determined that CNPV-RG has a relative potency of 3.5 lU/ml. The obtained results constituted the first stage of CNPV-RG evaluation as antirabic vaccine candidate. Further assays will be necessary to confirm its utility in species of veterinary Interest.
Descritores: Antígenos Virais/imunologia
Vírus da Varíola dos Canários/imunologia
Glicoproteínas/imunologia
Vacinas Antirrábicas
Proteínas do Envelope Viral/imunologia
-Anticorpos Antivirais/biossíntese
Anticorpos Antivirais/imunologia
Antígenos Virais/genética
Cercopithecus aethiops
Vírus da Varíola dos Canários/genética
Vírus da Varíola dos Canários/crescimento & desenvolvimento
Vírus da Varíola dos Canários/isolamento & purificação
Linhagem Celular/virologia
Fibroblastos/virologia
Glicoproteínas/genética
Rim
Mesocricetus
Fragmentos de Peptídeos/genética
Fragmentos de Peptídeos/imunologia
Vacinas Antirrábicas/imunologia
Raiva/prevenção & controle
Organismos Livres de Patógenos Específicos
Cultura de Vírus
Vacinas Sintéticas/imunologia
Células Vero/virologia
Proteínas do Envelope Viral/genética
Limites: Animais
Embrião de Galinha
Cricetinae
Camundongos
Responsável: AR1.2 - Instituto de Investigaciónes Epidemiológicas


  2 / 2 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-398121
Autor: Fischer, Elizabeth; Rieux, Véronique; Guillet, Jean-Gérard; Kazatchkine, Michel.
Título: The human immunodeficiency virus preventive vaccine research at the French National Agency for acquired immunodeficiency syndrome research
Fonte: Mem. Inst. Oswaldo Cruz;100(1):79-84, Feb. 2005. tab.
Idioma: en.
Resumo: The human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic is of unprecedented gravity and is spreading rapidly, notably in the most disadvantaged regions of the world. The search for a preventive vaccine is thus an absolute priority. For over 10 years the French National Agency for AIDS research (ANRS) has been committed to an original program combining basic science and clinical research. The HIV preventive vaccine research program run by the ANRS covers upstream research for the definition of immunogens, animal models, and clinical research to evaluate candidate vaccines. Most researchers in 2004 believe that it should be possible to obtain partial vaccine protection through the induction of a strong and multiepitopic cellular response. Since 1992, the ANRS has set up 15 phases I and II clinical trials in order to evaluate the safety and the capacity of the candidate vaccines for inducing cellular immune responses. The tested candidate vaccines were increasingly complex recombinant canarypox viruses (Alvac) containing sequences coding for certain viral proteins, utilized alone or combined with other immunogens (whole or truncated envelope proteins). ANRS has also been developing an original strategy based on the utilization of lipopeptides. These comprise synthetic fragments of viral proteins associated with lipids that facilitate the induction of a cellular immune response. These approaches promptly allowed the assessment of a prime-boost strategy combining a viral vector and lipopeptides.
Descritores: Vacinas contra a AIDS
Síndrome de Imunodeficiência Adquirida/prevenção & controle
HIV-1
Lipoproteínas/imunologia
-Síndrome de Imunodeficiência Adquirida/imunologia
Ensaios Clínicos Fase I como Assunto
Ensaios Clínicos Fase II como Assunto
Vírus da Varíola dos Canários/imunologia
França
Vetores Genéticos/imunologia
Limites: Seres Humanos
Responsável: BR1.1 - BIREME



página 1 de 1
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde